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Hemolytic uremic syndrome (HUS) from enterohemorrhagic Escherichia coli infection is a
leading cause of kidney failure in otherwise healthy U.S. children. The bacterial Shiga tox-
ins (Stx) induce the characteristic coagulopathy of HUS, but the damage to toxin-receptor
expressing cells and organ injury due to ischemia likely also releases inflammatory damage-
associated molecular patterns (DAMPs), which may exacerbate injury along with the toxins.
To examine this, human aortic and renal glomerular cell anti-coagulant and barrier functions
were studied after in vitro challenge with Stx1, Stx2, and DAMPs. There was signifi-
cant loss of surface anti-coagulant protein C pathway molecules, increased expression
of pro-thrombotic PAR1 and reduced protein C activation capability by 15–27%. Histones
nearly completely prevented the activated protein C protection of endothelial cells from
thrombin-induced permeability. In mice, lethal Stx2 challenge elevated plasma HMGB1
(day 2, 321±118%; p<0.01) and extracellular histones (day 3, 158±62%; p<0.01). Mice
colonized with Stx2-expressing Citrobacter rodentium developed increased HMGB1 (day
5, 155±55%; p<0.01) and histones (day 3, 378±188%; p<0.01). Anti-histone antibody
reduced both DAMPs to baseline, but was not sufficient to improve survival outcome or
kidney function. Together, these data suggest a potential role Stx to produce DAMPs, and
DAMPs to produce endothelial injury and a pro-thrombotic environment.
Keywords: hemolytic uremic syndrome, thrombotic microangiopathy, Shiga toxin 1, Shiga toxin 2, protein C,
damage-associated molecular patterns, endothelial cells
INTRODUCTION
Enterohemorrhagic Escherichia coli (EHEC) are toxigenic
intestinal bacteria that cause vomiting, diarrhea, edema, and
hemorrhagic colitis. In some patients, the disease can progress
to a potentially life-threatening syndrome known as diarrhea-
associated hemolytic uremic syndrome (D+HUS), character-
ized by thrombotic microangiopathy, thrombocytopenia, and
hemolytic anemia, all of which contribute to acute kidney injury
(1). In the U.S., D+HUS is a leading cause of acute kidney fail-
ure in otherwise healthy children (2). EHEC produce and secrete
Shiga toxin 1 (Stx1), Shiga toxin 2 (Stx2), or both, and serotypes
that secrete Stx2 are associated with more clinically severe disease
(3). Much of the pathogenesis observed during EHEC infection
is attributed to the toxins, which are considered primary viru-
lence factors of EHEC. The toxins bind to globotriaosylceramide
(Gb3, CD77) receptors whose distribution is particularly high
on renal glomerular endothelial cells in humans and on renal
tubular epithelium in mice (4–6). The toxins are then internal-
ized and transported to the endoplasmic reticulum, and the A
subunit is activated to generate RNA N -glycosidase activity (7).
Within the cytosol, the active A subunit cleaves an adenine residue
from 28S ribosomal RNA, which prevents protein synthesis (8–10)
and initiates ribotoxic (11, 12) and endoplasmic reticular-stress
responses (13), leading to apoptosis and inflammation.
A major clinical feature of D+HUS is thrombotic microan-
giopathy, in which clots form inappropriately in the microvascu-
lature, resulting in ischemic consequences and organ injury. As
endothelial cells are crucial for maintaining blood fluidity and
preventing leakage through the vessel walls, it is possible that Stx-
and inflammation-induced perturbations in these functions con-
tribute to the observed thrombotic microangiopathy. A critical
pathway mediating these functions is the protein C pathway, which
provides anti-coagulant, anti-inflammatory, and barrier protec-
tion activities (14). The activated form of the protein C zymogen
mediates these activities, and activated protein C (APC) is gen-
erated by the protease action of thrombin, which is localized to
the endothelial cell surface through binding to thrombomodulin
(TM). Generation of APC is further facilitated by the endothelial
protein C receptor (EPCR), which presents protein C zymogen to
the cell surface thrombin/TM complex for more efficient activa-
tion (15, 16). During in vitro studies using human renal glomerular
endothelial cells (HRGEC), Stx2-induced a small decrease in TM
antigen expression (17), but resultant functional changes were not
determined.
www.frontiersin.org April 2015 | Volume 6 | Article 155 | 1
Mayer et al. Stx and DAMPs induce endothelial dysfunction
As an anti-coagulant, APC inhibits coagulation cofactors Va
and VIIIa (18), but its barrier-protective activity is mediated by
its occupation of EPCR and subsequent activation of protease-
activated receptor 1 (PAR1). PAR1 is intimately involved in
endothelial barrier function, and signaling by this discriminatory
receptor is protease-specific depending on whether it is activated
by APC, thrombin, or other proteases (19–22). PAR1 activa-
tion by thrombin contributes to thrombosis while also increasing
endothelial barrier permeability; however,PAR1 activation by APC
in concert with EPCR elicits an opposite barrier-protective effect.
Although human endothelial cells express the Gb3 toxin recep-
tor, little is known about how the Shiga toxins impact expression
and function of PAR1, EPCR, and TM, and disruption of these
molecules can have significant consequences (23, 24).
Enterohemorrhagic Escherichia coli are generally non-invasive,
but the intestinal damage observed during EHEC infection can
be considerable, with inflammation, hemorrhage, edema, and
focal necrosis predominating (25). Often released by damaged
cells are molecules termed damage-associated molecular pat-
terns (DAMPs) (26): normal, endogenous molecules that can
be extruded from the cell into the blood or tissue. Examples
of DAMPs include histones, which can circulate or localize in
neutrophil extracellular traps (27), or HMGB1 from monocytes
(28). DAMPs also are released from necrotic cells, and circulating
DAMPs can activate many of the same receptors as pathogen-
associated molecular patterns to propagate inflammation and
tissue damage (29, 30). Some DAMPs also can cause endothe-
lial dysfunction manifested by increased permeability (31) or
increased platelet adhesion (27). Although it has not been repeat-
edly demonstrated that DAMPs are released in the context of
EHEC infection or Shiga toxin release, DAMPs from damaged
tissue increase in several patient and animal models of sepsis and
trauma (32–35). Given the extent of intestinal and kidney injury
after EHEC toxin challenge (36–38), and the relative paucity of
Shiga toxins observed in serum during hemolytic uremic syn-
drome (HUS) (39), we hypothesized that injury to any cell express-
ing the Gb3 receptor for Shiga toxins would release DAMPs, and
that those DAMPs compromise the antithrombotic and barrier-
protective properties of endothelial cells, leading to thrombotic
microangiopathy and HUS.
MATERIALS AND METHODS
REAGENTS
Plasma levels of HMGB1 and extracellular histones were mea-
sured using ELISAs for HMGB1 (IBL-international, Toronto, ON,
Canada, and Chondrex Inc., Redmond, WA, USA) and cell-death
detection (Roche, Indianapolis, IN, USA), respectively. Human
aortic endothelial cells (Cascade Biologics, Grand Island, NY, USA)
or HRGEC (Sciencell, Carlsbad, CA, USA) were purchased and
grown in endothelial cell medium (Sciencell) supplemented with
5% fetal bovine serum, 100 U/mL penicillin, 100µg/mL strep-
tomycin, endothelial cell growth supplements according to the
manufacturer’s instructions. These cell lines are morphologically
similar, but HAEC grow more quickly and form tighter junctions,
in addition to not being fenestrated as renal glomerular endothelial
cells are. All experiments were performed between passage 2 and
6. Antibodies were purchased against PAR1 (ATAP2, Santa Cruz
Biotechnology, Dallas, TX, USA, un/conjugated to Alexa 488), and
TM, clone 1029, conjugated to Oregon green, for flow cytometry,
and clone 1A4 for on-cell western (Becton Dickinson, Franklin
Lakes, NJ, USA). Anti-EPCR (JRK 1494, un/conjugated to Alexa
488) were available from C.T. Esmon (Oklahoma Medical Research
Foundation, Oklahoma City, OK, USA). Goat anti-mouse IRDye
800CW for use in on-cell westerns was purchased from Li-COR
(Lincoln, NE, USA). Stx1 and Stx2 were purchased from Tufts Uni-
versity and endotoxin was removed by incubation with polymyxin
B-agarose (Sigma Aldrich, St. Louis, MO, USA). Residual endo-
toxin levels were <0.015 ng/mL (LAL Chromogenic Endotoxin
Quantitation Kit, Thermo Scientific, Rockford, IL, USA). Hybrido-
mas producing anti-histone IgG clone BWA3 (40) were kindly
provided by Dr. Ann Rothstein (Department of Immunology and
Virology, University of Massachusetts Medical School, Worces-
ter, MA, USA) and the antibody was purified from conditioned
media using HiTrap Protein G columns (GE Healthcare, Pis-
cataway, NJ, USA) and standard methods. Calf thymus histones
and TNFα were purchased from Sigma Aldrich. Human plasma-
derived protein C was a kind gift from Kaketsuken (Kumamoto,
Japan). Spectrozyme PCa was purchased from American Diag-
nostica (Lexington, MA, USA), human α-thrombin, and anti-
thrombin III were from Hematologic Technologies, Inc. (Essex
Junction, VT, USA). All other reagents such as bovine serum
albumin (BSA), ethlyenediaminetetraacetic acid (EDTA), and 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were
laboratory or research grade and purchased from Sigma Aldrich
and ThermoFisher Scientific.
MOUSE MODEL OF Stx2 TOXEMIA
Mice were purchased from the Jackson Laboratories (Bar Harbor,
ME, USA) for all experiments. All animal studies were approved
by the Boston University Institutional Animal Care and Use Com-
mittee. Mice (6-week-old male C57BL/6J) were injected intraperi-
toneally with 1 ~ 1.2 ng Stx2/20 g bodyweight at day 0 and day 3.
Control mice received equal volumes of normal saline by intra-
peritoneal injection. Blood was collected into 5 mM EDTA by
facial vein bleed prior to each Stx2 challenge, and periodically until
euthanasia for downstream analyses, consistent with the IACUC-
approved protocols. Animals were monitored and weighed daily
and plasma blood urea nitrogen (BUN) was quantified as a marker
of acute kidney injury using a QuantiChrome Urea Assay Kit
(BioAssay Systems, Hayward, CA, USA).
MOUSE MODEL OF EHEC INFECTION
Mice (6-week-old female C57BL/6J) were inoculated with Cit-
robacter rodentium. This is a Gram negative mouse pathogen
that either was lysogenized with an Stx2-producing phage (strain
DBS770) in order to express the Shiga toxin, or a control strain
that does not express the toxin (strain DBS771). C. rodentium
strains were kindly provided by Dr. John M. Leong (Department
of Molecular Biology and Microbiology, Tufts University Medical
Center, Boston, MA, USA) and have been described in detail else-
where (41). Briefly, bacteria were grown in LB broth containing
chloramphenicol (final 10µg/mL) or both chloramphenicol and
kanamycin (25µg/mL) to an OD600 of 0.75–0.90. Bacteria were
washed, re-suspended in sterile saline, and mice were challenged
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with 1× 109 CFU by oral gavage on day 0. Weight was moni-
tored daily and plasma collected periodically by facial vein bleed.
CFU/g feces was determined by mixing feces with 10 volumes of
phosphate buffered saline (PBS) (ThermoScientific), homogeniz-
ing with a sterile toothpick, centrifuging 30 s at 4000 rpm, and
plating serially diluted supernatants on LB agar with appropriate
restrictive antibiotics. Plates were grown overnight at 32°C and
colonies were counted the next day.
FLOW CYTOMETRY
Human aortic endothelial cells between passage 2 and 6 were
seeded on 0.1% gelatin-coated plates at 1.5× 104 cells/cm2. The
next day, media was replaced with fresh media containing Stx1
or Stx2 (100 ng/mL), extracellular histones (50µg/mL), or combi-
nations. Cells maintained ≥85% viability under these conditions.
Cells were incubated for 24 h, washed with PBS and then detached
using Versene (Invitrogen) and passed through a 40µm nylon
mesh. All subsequent steps were done on ice. Cells were washed
in PBS with 25 mm HEPES, 0.5% BSA, and 5 mM EDTA, pH 7.4
(flow buffer) before staining with primary conjugated antibodies
(2µg/mL) for 30 min. Cells were washed again and re-suspended
in flow buffer. Dead cells were excluded by propidium iodide
staining. Cell associated fluorescence was determined using a FAC-
SCalibur flow cytometer (Becton Dickinson) and data analyzed
using FlowJo X (Treestar Inc., Ashland, OR, USA) software. Based
on peak morphology (one peak vs. bimodal), the geometric mean
or an M1 region expressed as a percentage was used for data
analysis. One-way ANOVA with a Dunnett posttest was used to
determine significant differences between geometric means or M1
regions at p< 0.05.
ON-CELL WESTERN
Antigen expression on HRGEC was done by on-cell western due
to difficulty in producing large numbers through passaging. On-
cell western was performed with aortic endothelial cells as well,
specifically to compare surface antigen expression with HRGEC at
baseline. Optimal toxin and histone concentrations that impacted
surface phenotype while maintaining cell viability were deter-
mined in preliminary dose–response studies. Cell viability was
maintained at 82–96% under experimental conditions (data not
shown). Black-walled, clear-bottomed 96-well tissue culture plates
(Corning, Tewksbury, MA, USA), of the type used for fluorescent
experiments, were coated with 0.1% gelatin and then seeded with
HRGEC (Sciencell) grown in endothelial cell media. When cells
were near confluent, media were replaced and challenges were
added. After 24 h, cells were washed once with PBS then fixed
for 20 min at room temperature in PBS with 3.7% formalde-
hyde. After fixation, cells were washed twice with 50 mM Tris, pH
7.4, 150 mM NaCl, 0.05% Tween-20 (TBST), and blocked with
Odyssey blocking buffer (Li-Cor, Lincoln, NE, USA) at room tem-
perature with gentle shaking. Following the blocking step, cells
were washed twice with TBST and incubated with primary uncon-
jugated antibodies for EPCR (JRK 1494), PAR1 (ATAP2), or TM
(1A4) at 2µg/mL in Odyssey blocking buffer. Cells were washed
twice with TBST and incubated with goat anti-mouse IRDye
800CW (Li-Cor) diluted 1:800 in Odyssey blocking buffer and
Draq5 (5 mM stock, Thermo Scientific) diluted 1:10,000. Plates
were washed with TBST, and all liquid aspirated before read-
ing fluorescent values on a Li-Cor Odyssey dual-channel infrared
imager at 700 and 800 nm. Images were analyzed with Odyssey
2.1 software (LiCor), and fluorescent intensities at 800 nm were
normalized to intact cell number based on Draq5 staining at
700 nm. One-way ANOVA with a Dunnett posttest was used to
determine significance.
PROTEIN C ACTIVATION ASSAY
Confluent human aortic endothelial cells (HAEC) were incubated
with Stx1 (100 ng/mL), Stx2 (100 ng/mL), calf thymus histones
(50µg/mL), or combinations. Confluent HRGEC were challenged
with Stx1 (50 ng/mL), Stx2 (50 ng/mL), or histones (50µg/mL).
For experiments with anti-histone BWA3 monoclonal antibody,
endothelial cells were challenged with 30µg/mL histones with or
without BWA3 at 20µg/mL. All challenges were done for 24 h at
37°C in 5% CO2. Cells were washed with Hank’s balanced salt
solution (HBSS; Thermo) and protein C was added at a final con-
centration of 0.4µM in 0.1 mM HEPES, pH 7.4, 0.6 mM MgCl2,
and 1 mM CaCl2. Human α-thrombin (10 nM final) was added
and the reaction was stopped after 30 min at 37°C with HBSS,
0.1 mM HEPES, 0.5 mg/mL human ATIII, and 1.4 U/mL heparin.
Spectrozyme PCa (American Diagnostica, Lexington, MA) was
added (0.2µM final) and the change in absorbance 405 nm with
time was performed on a VersaMax ELISA Microplate Reader and
analyzed with SoftMax Pro 5.4 (Molecular Devices, Sunnyvale,
CA, USA). APC levels were determined by reference to a stan-
dard curve prepared with purified human APC, and normalized
to intact cell numbers determined using Draq5 staining of a paral-
lel plate, then normalized to 100% activation by unchallenged cells.
One-way ANOVA with a Dunnett posttest was used to determine
significant differences.
ENDOTHELIAL CELL PERMEABILITY
Endothelial cell monolayer permeability changes were quanti-
fied from changes in electrical resistance across a human aor-
tic endothelial monolayer as monitored by electric cell-substrate
impedance sensing using an ECIS® ZO array station (Applied
Biophysics, Troy, NY, USA). For each experiment, two 40 elec-
trode/well 8W10E+ electrode chamber slides (Applied Bio-
physics) were coated with 10 mM l-cysteine/well for 10 min,
washed 2 times with HBSS, coated with 5µM fibronectin in HBSS
for 10 min, then washed 2 times more with HBSS and allowed
to dry. HAEC between passages 2 and 6 were seeded at a den-
sity of 2.5× 105 cells/chamber and allowed to adhere and form a
monolayer as determined by the stabilizing capacitance at 64 kHz.
For experiments with pre-treatments, histones (25µg/mL) or Stx2
(100 ng/mL) were added to the appropriate wells 12 h before
thrombin addition. Thrombin was added to 1 U/mL (16.85 nM)
and the experiment was followed for at least 12 h after thrombin
addition. For experiments using APC, concentrations of thrombin
were lowered to 2 nM in order for the protective effect of APC on
PAR1 to be observed (19). Pre-incubation with APC (10 nM) was
done for 3 h prior to thrombin challenge. The area under the curve
for normalized resistance over the selected range of time was deter-
mined and one-way ANOVA with a Dunnett posttest was used to
determine significance.
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RESULTS
LARGE VESSEL ENDOTHELIUM EXPRESSES MORE SURFACE EPCR,
PAR1, AND TM ANTIGEN THAN MICROVASCULAR RENAL
ENDOTHELIUM
Differential endothelial expression of EPCR and TM is well-
recognized, and while TM is widely expressed, surface EPCR
expression is known to increase with vessel size (42). Relative quan-
titation of TM and EPCR levels in different vascular beds is not
well established, particularly for renal endothelium. In order to
better interpret the impact of Stx and DAMPs on receptor expres-
sion, quantitative comparisons of baseline surface EPCR, PAR1,
and TM on the surface of normal, unchallenged HAEC, repre-
senting large vessel endothelium, and HRGEC, representing small
vessel endothelium, were performed. These experiments differed
from those involving Stx and DAMP challenges in that they were
accomplished by performing on-cell westerns with both cell types.
We observed that at baseline HAEC expressed significantly higher
antigen amounts of EPCR (7.4-fold), PAR1 (1.8-fold), and TM
(3.2-fold) when compared to HRGEC (Figure 1).
Stx AND DAMPs SHIFT ENDOTHELIAL EXPRESSION OF PAR1 AND
PROTEIN C PATHWAY MOLECULES
The abilities of the Shiga toxins and histone DAMPs to alter surface
expression of endothelial cell molecules have important implica-
tions for maintaining blood fluidity and were determined by flow
cytometry with HAEC (Figure 2). HAEC challenged with his-
tones demonstrated significantly increased expression of thrombin
receptor PAR1 relative to control cells (Figure 2A; p< 0.001),
whereas challenge with either Stx1 or Stx2 caused a subset of
cells (35–40%) to significantly lower their surface expression of
PAR-1 (Figure 2B; p< 0.001). EPCR surface antigen expression
was reduced significantly relative to media alone in cells incubated
with histones or Stx (Figures 2C,D; p< 0.001). TM expression was
FIGURE 1 | Different endothelium express different amounts of PAR1,
EPCR, andTM. Surface expression of EPCR, PAR1, and TM on large vessel
human aortic endothelial cells (HAEC, black) and microvascular human renal
glomerular endothelial cells (HRGEC, checkered). The significance is
determined by comparing the amount of EPCR, PAR1, or TM on each cell
type in unchallenged cells at 24 h. Constitutive expression of EPCR, PAR1,
and TM on both HAEC and HRGEC for this figure was determined by on-cell
western, as described in Section “Materials and Methods.” Comparison
was done by two-way ANOVA with a Bonferroni posttest. **p<0.01,
***p< 0.001.
reduced after histone treatment (Figure 2E; p< 0.001); however,
Shiga toxins did not affect TM levels (Figure 2F).
As the primary target organ of the toxins in humans is the
kidney glomerular endothelium, HRGEC were challenged simi-
larly to aortic endothelial cells (Figure 3). The renal cells are more
sensitive to the histones and toxins in vitro (data not shown), so
challenge concentrations were decreased to maintain>80% viabil-
ity and on-cell western was used to minimize manipulation of the
cells. Stx1 and Stx2 challenge reduced PAR1 (Figure 3A), EPCR
(Figure 3B), and TM surface expression (Figure 3C). Histones
did not appreciably alter PAR1 or TM expression, but did decrease
EPCR expression on HRGEC.
HISTONES REDUCE ENDOTHELIAL ACTIVATED PROTEIN C GENERATION
Functional changes resulting from alterations to surface expression
of TM or EPCR ought to include changes to the rate of protein
C activation. To determine if surface expression level changes of
TM or EPCR correlated with functional changes that could be
extrapolated to have significance in the development of HUS,
the rate of protein C activation was determined on endothelial
cells after challenge with Stx or histone DAMPs. Only Stx1 or
histones had significant effects on the activation of protein C in
aortic endothelial cells (Figure 4A). Histone challenge of HRGEC
led to a significant decrease in the rate of protein C activation at
24 h post-challenge (Figure 4B; p< 0.001); however, neither Shiga
toxin alone caused a significant difference in the amount of pro-
tein C activated. The suppression of protein C pathway function by
histones was successfully prevented in the presence of anti-histone
monoclonal antibody BWA3, which inhibits H4 and H2a (40), and
protein C activation was restored on both aortic and glomerular
endothelial cells in the presence of the blocking antibody during
challenge with histones (Figures 4C,D).
HISTONES BUT NOT Stx ENHANCE THROMBIN-INDUCED LOSS OF
ENDOTHELIAL BARRIER FUNCTION
Along with their roles in anticoagulation, both endothelium and
APC have important roles in maintaining a selective barrier in the
vasculature. Endothelial cell permeability changes in response to
Stx and histones were examined by monitoring the resistance of
a human aortic endothelial monolayer in a continuous fashion
using an electrical cell impedance system. As expected, thrombin
(1 U/mL final) stimulation resulted in a rapid decrease in resistance
(Figure 5A), which correlates with increased permeability. How-
ever, in cells pre-treated for 12 h with histones (25µg/mL) prior
to thrombin stimulation, the thrombin-induced barrier function
decrease was prolonged (Figure 5B). Recovery to pre-treatment
levels following thrombin stimulation occurred after ~2 h; recov-
ery from thrombin on histone-treated endothelium had not yet
occurred by 18 h post-challenge (data not shown for presentation
purposes). Pre-treatment with APC abrogated thrombin’s effect on
monolayer permeability (Figure 5C), consistent with the known
barrier protection properties of APC. APC was not able to rescue
the loss of cell permeability due to thrombin when the cells were
pre-treated with histones (Figure 5C), and treatment with histones
alone did not increase permeability (data not shown). Stx2 did not
change the duration of increased permeability of HAEC to throm-
bin, and APC was able to restore cells from thrombin-induced leak
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FIGURE 2 | Stx1, Stx2, and histones induce changes in aortic endothelial
expression of surface molecules. Human aortic endothelial cells were
challenged with 50µg/mL histones (A,C,E) or 100 ng/mL Stx1 (B,D,F) and
surface expression of PAR-1, EPCR, and TM were quantified by flow
cytometry using antigen-specific antibodies. Histogram overlays show
representative staining of unchallenged cells (gray) and challenged cells (dark)
compared to background staining (unfilled), with challenges represented
using Stx1, as there were no differences in effect with respect to which Shiga
toxin was used. Bar graphs show geometric means±SD of three to four
experiments each, except (B), which compares the M1 region 1, expressed
as a percentage. Differences from constitutive expression (media
only=100%) are shown as ***p<0.001.
FIGURE 3 | Stx1, Stx2, and histones induce changes in renal glomerular
endothelial expression of surface molecules. Surface expression of (A)
PAR1, (B) EPCR, and (C)TM were quantified by on-cell western after 24 h
incubation with Stx1 (50 ng/mL), Stx2 (100 ng/L), or 50µg/mL histones.
Antigen data were normalized to cell number using Draq5 staining.
Differences from media alone are shown as ***p< 0.001.
regardless of whether or not Stx2 was present (Figure 5D). Chal-
lenge with Stx1 did not alter these results. The area under the
curves was calculated to quantify the relative effects (Figure 5E).
Thus, under these conditions, histone DAMPs greatly exacerbate
thrombin’s impact and prevent APC from being protective, though
the toxins do not appreciably change endothelial barrier function.
DAMPs ARE PRESENT IN THE PLASMA OF Stx2-CHALLENGED MICE
In order to determine whether Stx2 challenge produces DAMPs
in mice, we used two different mouse models: a Stx2-toxemia
model, and a Stx2-producing bacterial model. Mice challenged
with Stx2 (1 ng/20 g body weight; i.p.) on day 0 and day 3 exhibited
decreased survival (Figure 6A, dashed line) and kidney injury evi-
denced by increasing BUN relative to saline controls (Figure 6B;
p< 0.001 on day 4). Plasma histone levels in Stx2 challenged mice
were significantly elevated on day 3 post-challenge (258%± 62%
n= 24) when compared to day 0 (Figure 6C). Plasma levels of
HMGB1, another DAMP associated with disease severity in sepsis
models, were significantly elevated by 2 days after Stx2 challenge
(421%± 117%; n= 13) when compared to day 0 (Figure 6E).
Pre-treatment with anti-histone BWA3 antibody prevented the
significant rise in plasma histones (Figure 6D). Surprisingly, pre-
treatment with anti-histone BWA3 antibody also abrogated the
rise in HMGB1 (Figure 6F). Despite the reduction in circulating
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FIGURE 4 | Challenge with Stx or histones decreases activation of
protein C. The ability of human aortic endothelial cells (A,C) or renal
endothelial cells (B,D) to activate protein C after 24 h challenge with Stx1,
Stx2, or histones was determined on confluent monolayers with 10 nM
human alpha-thrombin and 0.2µM human protein C at 37°C. Activated
protein C was quantified in cell supernatants with spectrozyme PCa
substrate and converted to nM APC using a standard curve, then adjusted
for cell number with Draq5 staining. Anti-histone antibody BWA3 (20µg/mL)
was added before challenge in some wells. Differences relative to media
alone are shown as *p<0.05, **p<0.01, ***p< 0.001.
DAMPs by antibody, there was no alteration in survival outcome
after lethal Stx2 challenge (Figure 6A, dotted). This result was not
wholly unexpected, as the renal damage in mice is centered more
in the tubular epithelium and collecting ducts, as opposed to the
renal glomerular endothelium in humans, and the mice do not
display thrombotic microangiopathy.
During EHEC infection, Stx exposure occurs over days as the
gut is colonized by EHEC that produce and release the Shiga tox-
ins, so we also utilized a murine model in which mice are infected
by oral gavage with C. rodentium strains that either do or do not
express Stx2. The intestinal attaching/effacing lesions and contri-
butions of Stx2 toward organ injury have been described (41), and
this model has been shown to produce similar A/E lesions and thus
be more relevant than a Stx2-alone model. Inoculating the mice by
oral gavage with ~1× 109 CFU of C. rodentium-Stx2 resulted in
decreased survival (Figure 7A; dashed line) compared to mice that
received control C. rodentium, which does not express the toxin.
As expected, kidney injury was toxin-dependent as evidenced by
elevated plasma BUN by days 7–9 with the toxin-producing strain
(Figure 7B; p< 0.001 on day 9). Mice challenged with non-Stx2
producing C. rodentium (open circles) did not develop changes
in plasma levels of extracellular histones for the duration of the
experiment when compared to day 0 (Figure 7C). In contrast,
mice challenged with C. rodentium-Stx2 (black squares) devel-
oped significantly increased plasma levels of histones on day 3.
This effect was significant when compared their own day 0 val-
ues and was also significant compared to plasma histone levels in
non-Stx2 producing C. rodentium challenged mice (Figure 7D).
Plasma HMGB1 did not increase significantly in mice challenged
with non-Stx2 producing C. rodentium (Figure 7F), in contrast
to elevated levels of HMGB1 by day 5 in C. rodentium-Stx2 mice
(Figure 7G). BWA3 anti-histone antibody pre-treatment (dotted
line) did not alter survival. Survival was still significantly decreased
(p< 0.001) compared to animals challenged with C. rodentium
not expressing Stx2, and there was no significant difference when
compared with mice given Stx2-expressing C. rodentium and no
antibody pre-treatment. The observed increase in plasma his-
tone and HMGB1 levels were abolished by treatment with the
anti-histone BWA3 antibody (Figures 7E,H). In conclusion, both
murine models demonstrated that DAMPs were consistently ele-
vated when Stx2 was present, and in both cases the rise occurred
prior to rise in BUN, confirming that in the presence of Stx2,
DAMPs are produced.
DISCUSSION
LOW RELATIVE EXPRESSION OF PROTECTIVE EPCR AND TM ON RENAL
GLOMERULAR ENDOTHELIAL CELLS
Differential expression of EPCR and TM between large vessel
endothelium and the microvasculature is known from immuno-
histochemistry studies, particularly for EPCR, which is expressed
relatively more on large vessel endothelium (42). Here, we provide
quantitative assessment of EPCR, TM, and PAR1 expression on
cultured primary endothelial cells using on-cell western. Our
results show that there are 3.2-fold lower and 7.4-fold lower
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FIGURE 5 | Histones, but not Stx, contribute to increased
endothelial cell permeability and block APC rescue. Permeability of
human aortic endothelial cells was determined by monitoring changes in
electrical resistance across a monolayer as described in Section
“Materials and Methods.” (A) Steady state resistance observed with
media (o) decreases after addition of 1 U/mL (16.85 nM) human thrombin
(•), reflecting increased permeability. Challenge with Stx2 (∆) lead to no
change in permeability. (B) Increased permeability after thrombin (•)
challenge is significantly prolonged if cells are pre-exposed to 50µg/mL
histones (X) for 12 h, but again, Stx2 causes no appreciable change in
permeability (∆). (C) Compared to thrombin (2 nM) alone (•), APC
pre-exposure (?) attenuates thrombin effects on permeability, but cannot
rescue permeability of the cells if they have also been exposed to
histones (N). (D)Thrombin increased permeability (•) and APC rescued
cells (?), but adding 100 ng/mL Stx2 (H) did not change the protective
effect of APC. (E) Permeability data were quantified as area under the
curves; mean±SD of three to four experiments each. Neither Stx1 nor
Stx2 alone altered electrical resistance of the monolayers and so Stx2 is
shown on graphs as representative of either Shiga toxin. *p<0.05,
***p<0.001.
expressions of TM and EPCR, respectively, on renal glomeru-
lar endothelial cells when compared with aortic endothelial
cells in the same experiment. APC is protective in acute kid-
ney injury murine models (43), and the organ system most
vulnerable to the sequelae of low EPCR expression is the kid-
ney, which demonstrates enhanced albuminuria and profound
renal hemorrhage after LPS challenge (44). The kidneys are
already a toxin target due to glomerular Gb3 expression, and
the current data suggest that further reduction due to toxin
and DAMP exposure of already low TM and EPCR expression
may provide an environment highly susceptible to thrombus
production.
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FIGURE 6 | Plasma DAMPs increase after Stx2 challenge in mice. Mice
were challenged i.p. with 1 ng/20 g body weight Stx2 [bold dashed line in (A),
black squares in (B–F), n=45] or saline [solid line in (A), open circle in (B),
n=15] on Day 0 and Day 3 and monitored for (A) survival and (B) plasma
BUN. Plasma histones (C,D) and HMGB1 (E,F) were measured by ELISA.
One group received a bolus dose of anti-histone BWA3 (400µg i.p.) before
challenge [(D,F); n=5]. Survival was not influenced by BWA3 [(A), dotted;
n=5]. *p<0.05, **p<0.01, ***p<0.001.
IN VITRO LOSS OF EPCR AND TM SURFACE EXPRESSION ON
ENDOTHELIAL CELLS DUE TO Stx AND DAMPs
D+HUS is characterized by thrombotic microangiopathy, or a
forming of microthombi in the small vasculature of the glomeru-
lus, suggesting loss of endothelial anti-coagulant capacity. The
receptors and enzymes that make up the protein C pathway of
endothelial cells are critical contributors to intact anti-coagulant
function of the endothelium and loss of these anti-coagulant and
cytoprotective molecules could have significant pro-thrombotic
consequences. Surface expression levels of protein C pathway mol-
ecules are changed in Shiga toxin- or DAMPs-challenged human
endothelial cells, as demonstrated here in vitro. Shiga toxin and/or
DAMP challenge of human endothelial cells resulted in a shift
toward a pro-coagulant environment, and this has functional con-
sequences with respect to the generation of APC,an enzyme critical
in controlling thrombus formation. We made several significant
observations, including reduced APC generation, enhancement of
endothelial barrier permeability, and reduction of the ability of
APC to protect barrier function in the context of Stx or histone
DAMP challenge. These data provide insights into the mecha-
nism of Stx-induced endothelial dysfunction in D+HUS and
strongly suggest a potential role for tissue damage induced DAMPs
in this process.
Thrombin bound to TM preferentially cleaves and activates
protein C instead of fibrinogen (45), creating APC and ultimately
reducing fibrin clot formation. EPCR makes the thrombin/TM
cleavage of protein C even more favorable. EPCR also plays a
crucial role in endothelial function because APC/EPCR complex
activation of PAR1 leads to a cytoprotective signaling cascade (19,
46, 47). We previously demonstrated in a non-human primate
model of HUS that Shiga toxins alone can cause HUS and acute
renal failure with fibrin deposition and swelling and detachment
of glomerular endothelial cells (48, 49). Cellular mechanisms are
difficult to study in non-human primates and mouse models do
not develop the coagulopathy of HUS, so the current study with
human cells extends the in vivo observations by demonstrating
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FIGURE 7 | Plasma DAMPs increase during intestinal infection with
Stx2+ Citrobacter rodentium. Mice were gavaged with 1×109 CFU
Stx2+ C. rodentium [bold dashed line in (A), black square in (B,D,E,G,H),
n=15] or Stx2− strain C. rodentium [solid line in (A), open circle in
(B,C,F), n=10] on Day 0 and monitored for (A) survival and (B) plasma
BUN. Plasma DAMPs were measured as histones or HMGB1 in
Stx2− mice (C,F) and Stx2+ mice (D,G). Baseline levels of both DAMPs
were observed when anti-histone antibody BWA3 (400µg; i.p.) was
injected 10 min prior to challenge with Stx2+ bacteria [(E,H);
n=5/group]. Pre-treatment with BWA3 did not affect survival after
challenge with the Stx2+ strain [(A), dotted line; n=5]. *p<0.05,
**p<0.01, ***p<0.001.
in vitro loss of EPCR and TM surface expression on endothelial
cells due to Stx and DAMPs, particularly histones, and reduced
capacity to generate APC. A pro-thrombotic environment is fur-
ther created by DAMP-induced increased expression of PAR-1, the
pro-thrombotic thrombin receptor (50). Both histones and Shiga
toxins reduced EPCR expression, and Shiga toxins also lowered
TM on HRGEC, with the end result that both Stx1 and histones
affected the amount of APC generated by HRGEC in HAEC, with
histones alone affecting APC production in HRGEC.
LOSS OF IN VITRO ENDOTHELIAL BARRIER FUNCTION DUE TO
HISTONES BUT NOT Stx
D+HUS patients can develop edema, and in our system we
observed loss of in vitro endothelial barrier function primar-
ily due to histones, rather than through any effect of Stx1 or
Stx2 on endothelial cells. Histones increased PAR-1 and lowered
EPCR expression and pre-treatment of human aortic endothe-
lial monolayers with histones significantly delayed the ability of
the endothelial barrier to recover to baseline after thrombin chal-
lenge. Histones also significantly inhibited the barrier-protective
effects of APC. It is possible that histones might compete as a
substrate for APC (32), but we did not find any effect of histones
on APC chromogenic activity even at histone concentrations up
to fourfold higher than those used here (data not shown). PAR1
can function in both barrier protective and disruptive capacities,
depending on which protease cleaves it and whether EPCR is occu-
pied by a ligand. Shiga toxins and DAMPs both decrease the surface
ratio of EPCR:PAR1 by lowering EPCR; however, only histones
also raise PAR1, which could account for the differential effects
of histones vs. Shiga toxins with respect to APC inhibition. We
hypothesize that the combination of decreased EPCR along with
increased PAR1 creates more opportunity for thrombin signaling
while dampening the potential protective effects of EPCR occupied
with APC, helping to explain the prolongation of the permeability
effects of thrombin despite its use.
DAMPs ARE PRODUCED BY THE ACTION OF SHIGA TOXINS IN MICE
The purpose of our mouse models was to demonstrate that
DAMPs are produced by the action of Shiga toxins. The finding
of significantly elevated DAMPs is to the best of our knowledge
a novel finding in mouse models of Shiga toxin challenge and is
consistent with prior studies in our non-human primate Stx-HUS
models (51). The finding that levels of plasma HMGB1 in both
mouse models decreased after an initial significant rise instead
of continuing to rise with disease severity could be due to the
limitations of current mouse models for this disease, because the
distribution of Gb3 receptors in the mouse differs from that in
humans or non-human primates (4, 5, 49). Unlike in human
kidneys, Shiga toxins target renal tubule epithelial cells in mice
(6) giving rise to the possibility that HMGB1 was excreted as
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urination becomes increasingly excessive in the mouse models due
to tubular injury. In contrast, humans and baboons express Gb3 on
endothelial cells, particularly in the glomeruli, and disease severity
is accompanied by progressive anuria so that the baboon Stx chal-
lenge models have and increase in certain plasma DAMPs such as
mitochondrial DNA over time (35). However, in contrast, we have
previously shown that HMGB1 in non-human primate models
also initially rises before dropping (51), so the waxing or waning
pattern of different DAMPs in the serum with Shiga toxin chal-
lenge likely relies on mechanisms that remain to be understood
and fall outside the scope of this discussion.
In our experiments, we introduced the anti-histone antibody
BWA3, which targets H4 and H2a, and is derived from an autoim-
mune mouse model (40). A bolus dose of 400µg BWA3 prior to
Stx2 or C. rodentium-Stx2 significantly decreased plasma levels of
histones and HMGB1, although in neither case was the outcome
altered for the model. These results suggest that these DAMPs may
function more as markers of cell injury in these murine models
rather than driving pathology as they might in other models; how-
ever, it was not our intention to investigate endothelial injury in
our murine models, for reasons, which have been stated already.
For this purpose, we turned to in vitro models of endothelial cell
injury. Our human endothelial cell experiments show a significant
impact by DAMPs with respect to APC generation and endothelial
dysfunction, but this is not possible to replicate in the mice, as these
models exhibit Stx-induced tubular epithelial injury (5), with no
evidence of glomerular endothelial damage, thrombotic microan-
giopathy, or thrombocytopenia of HUS as stated before. These
are limitations of all mouse models using endotoxin-free Stx chal-
lenge. Other investigators have shown that in mice challenged with
LPS (a model of endothelial cell injury) BWA3 reduced circulat-
ing histones and improved survival (32). The current experiments
with human endothelial cells raise the possibility that BWA3 might
have more of an effect on outcomes in models of kidney injury
driven by endothelial rather than tubular damage, such as a non-
human primate model that more closely mimics human pathology
(36, 37, 49); however, there are clear limitations to doing the exper-
iments described in this paper in non-human primates, and so we
chose to progress as described.
Elevated HMGB1 and histones have been shown experimen-
tally to be involved in SIRS development by the fact that inhibition
of either is beneficial in animal models of LPS-induced inflamma-
tion (32, 33). Currently, development of HUS in patients during
EHEC infection is largely attributed to the bacterially produced
Shiga toxin effects on endothelium or platelets (52), but the cur-
rent data suggest that the host response to injury contributes as
well. During active infection, Shiga toxins rapidly become unde-
tectable in the plasma days before development of HUS (39).
During this time, cells internalize the toxins, the intestinal bac-
teria damage the intestinal epithelium, and both processes may
lead to release of DAMPs. The observations made here can-
not link DAMP activities directly to susceptibility of patients to
develop HUS, but they do provide insight into a possible molec-
ular basis for development of increased vascular permeability and
a pro-thrombotic environment in the context of Stx2-induced tis-
sue damage. We showed this by demonstrating that DAMPs are
produced by the Shiga toxins, and that histone DAMPs cause
demonstrable endothelial dysfunction in two types of human
endothelial cells.
LIMITATIONS OF THE CURRENT STUDY AND FUTURE DIRECTIONS
While we have made several important observation in the experi-
ments described here promoting a possible role for Stx2-induced
DAMPs in the development of endothelial dysfunction underlying
HUS, there are still important questions that remain unanswered.
We did not identify cellular mechanisms linking Shiga toxins
and extracellular histones to the regulation of EPCR, TM, and
PAR1 endothelial expression, as we were more interested in the
end consequence of reduced protein C activation; however, this
mechanism could also be a source of potential therapeutic targets
and warrants investigation. Matrix metalloproteinases and MAPK
pathways may contribute to EPCR shedding (53, 54), though how
these may be impacted by Stx or DAMPs in this context was not
addressed. Histones act through TLR4 (55), which might induce
PAR1 through a similar mechanism, though we do not address
this here. Finally, Stx1 and Stx2 interact with human neutrophils
via TLR4 (56), but how that might impact histone or other DAMP
activities is not known. Pilot experiments using TAK-1, JNK, and
IRAK1/4 inhibitors demonstrated no significant prevention of
Shiga toxin effects on EPCR, PAR1, or TM (data not shown). The
largest limitation of our studies was the lack of a mouse model
demonstrating full-spectrum HUS, which to date has only been
reproducibly done by adding LPS to the Stx challenge (6, 57, 58).
Ideally, we would test our hypothesis in vivo using animal models
that demonstrate kidney injury driven by endothelial dysfunction,
and then we could show whether DAMPs are playing a significant
role by using therapies such as BWA3 and quantifiable outcomes
such as biomarkers and survival. Additionally, quantifying the
presence of DAMPs in the blood of patients with HUS would
be a good next step prior to experiments with full-spectrum HUS
animal models. Previous work has already amply demonstrated
the pathology and tissue damage (25, 59), and quantifying the
DAMPs that are almost certainly present would provide the evi-
dence needed to investigate whether they function as markers of
disease impact or drivers of disease. The data here lay ground-
work, giving evidence that this could be a fruitful path for future
investigations.
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